Navigation

P1

Poster
Influence of combined therapy on inflammatory state and pro-inflammatory cytokines in patients with coronary artery disease and metabolic syndrome

J. Uzokov1, A. Alyavi1, S. Azizov1, B. Alyavi1 (1Tashkent UZ)


Background and Aims:

Aim of the study was to investigate the influence of combined lipid lowering therapy with rosuvastatin and ezetimibe on lipid profile, inflammatory state and pro-inflammatory cytokines in dyslipidemic patients with coronary heart disease (CHD) and metabolic syndrome (MS).

Material and Methods:

128 patients with CHD and MS were randomly divided into two groups per 64. First group was provided rosuvastatin (10 mg) + ezetimibe (10 mg) and the second group (control) was provided only rosuvastatin (10 mg). Plasma lipids, inflammatory state (hs-CRP), and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) were measured at baseline and in 12 weeks.

Results

The level of TC, LDL-C was decreased significantly in combination group than controls (P<0.05), however there was not significant difference between 2 groups on HDL-C (P>0.05). Hs-CRP was decreased by 38% in the first group (P=0.003) vs. 31% in control group (P=0.005) from baseline, however there was no obvious changes between 2 groups. Even though, pro-inflammatory cytokines: TNF-α (from 1.42±0.98 to 0.87±0.18 in 12 weeks, P=0.018), IL-6 (from 7.8 pg/mL to 4.1 pg/mL, P=0.012), IL-1β (from 28.4±19.5 pg/ml to 17.5±15.8 pg/ml, P=0.010) in the combination group vs. TNF-α (from 1.48±1.12 to 1.12±0.25, P=0.047), IL-6 (from 8.0 pg/mL to 5.9 pg/mL, P=0.037), IL-1β (from 29.6±20.6 pg/ml to 20.6±17.4 pg/ml, P=0.040) significantly decreased in both groups from baseline however, there were statistically significant changes observed only in the first group (P<0.05) when compared two groups.

Conclusions:

Therapy with rosuvastatin and ezitemibe is superior than rosuvastatin alone to improve TC, LDL-C and pro-inflammatory cytokines in patients with CHD and MS.

    
        Array
(
    [id] => 1
    [abstract_id] => 15
    [session_id] => 1
    [pres_nbr] => P1
    [updated] => 
    [created] => 0000-00-00 00:00:00
    [abstract] => Array
        (
            [id] => 15
            [user_id] => 9
            [contact_id] => 9
            [knr] => 5c95ceb6
            [titel] => Influence of combined therapy on inflammatory state and pro-inflammatory cytokines in patients with coronary artery disease and metabolic syndrome

            [text] => 

Background and Aims:

Aim of the study was to investigate the influence of combined lipid lowering therapy with rosuvastatin and ezetimibe on lipid profile, inflammatory state and pro-inflammatory cytokines in dyslipidemic patients with coronary heart disease (CHD) and metabolic syndrome (MS).

Material and Methods:

128 patients with CHD and MS were randomly divided into two groups per 64. First group was provided rosuvastatin (10 mg) + ezetimibe (10 mg) and the second group (control) was provided only rosuvastatin (10 mg). Plasma lipids, inflammatory state (hs-CRP), and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) were measured at baseline and in 12 weeks.

Results

The level of TC, LDL-C was decreased significantly in combination group than controls (P<0.05), however there was not significant difference between 2 groups on HDL-C (P>0.05). Hs-CRP was decreased by 38% in the first group (P=0.003) vs. 31% in control group (P=0.005) from baseline, however there was no obvious changes between 2 groups. Even though, pro-inflammatory cytokines: TNF-α (from 1.42±0.98 to 0.87±0.18 in 12 weeks, P=0.018), IL-6 (from 7.8 pg/mL to 4.1 pg/mL, P=0.012), IL-1β (from 28.4±19.5 pg/ml to 17.5±15.8 pg/ml, P=0.010) in the combination group vs. TNF-α (from 1.48±1.12 to 1.12±0.25, P=0.047), IL-6 (from 8.0 pg/mL to 5.9 pg/mL, P=0.037), IL-1β (from 29.6±20.6 pg/ml to 20.6±17.4 pg/ml, P=0.040) significantly decreased in both groups from baseline however, there were statistically significant changes observed only in the first group (P<0.05) when compared two groups.

Conclusions:

Therapy with rosuvastatin and ezitemibe is superior than rosuvastatin alone to improve TC, LDL-C and pro-inflammatory cytokines in patients with CHD and MS.

[pres_form] => [bio_presenting_author] => [german_presentation] => 0 [contact_complete] => 1 [authors_complete] => 1 [abstract_complete] => 1 [images_complete] => 1 [confirmation_complete] => 1 [updated] => [created] => 2018-12-12 20:21:42 [sprache] => en [atherosclerosis_basic] => 0 [atherosclerosis_clinical] => 0 [heartfailure_basic] => 0 [heartfailure_clinical] => 0 [arrhythmia_basic] => 0 [arrhythmia_clinical] => 0 [hypertension_diabetes_dyslipidemia] => 1 [preventive_medicine] => 0 [contact] => stdClass Object ( [id] => 9 [user_id] => 9 [anrede] => 1 [akad_titel] => 1 [vorname] => Jamol [name] => Uzokov [institution] => Republican specialized scientific practical medical center of therapy and medical rehabilitation [department] => [adresszeile1] => 4 Osiyo Street [adresszeile2] => [adresszeile3] => [plz] => 100084 [ort] => Tashkent [land] => UZ [email] => jml_uz@yahoo.com [telefon] => [lang] => [updated] => [created] => 0000-00-00 00:00:00 ) [authors] => Array ( [0] => stdClass Object ( [id] => 14 [abstract_id] => 15 [vorname] => Jamol [name] => Uzokov [qualification] => [institution] => Republican specialized scientific practical medical center of therapy and medical rehabilitation [ort] => Tashkent [land] => UZ [sort] => 1 [is_presenting_author] => yes [updated] => [created] => 0000-00-00 00:00:00 ) [1] => stdClass Object ( [id] => 15 [abstract_id] => 15 [vorname] => Anis [name] => Alyavi [qualification] => [institution] => Republican specialized scientific practical medical center of therapy and medical rehabilitation [ort] => Tashkent [land] => UZ [sort] => 2 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) [2] => stdClass Object ( [id] => 44 [abstract_id] => 15 [vorname] => Shukhratjon [name] => Azizov [qualification] => [institution] => Tashkent Pediatric Medical Institute [ort] => Tashkent [land] => UZ [sort] => 4 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) [3] => stdClass Object ( [id] => 45 [abstract_id] => 15 [vorname] => Baxrom [name] => Alyavi [qualification] => [institution] => Republican specialized scientific practical medical center of therapy and medical rehabilitation [ort] => Tashkent [land] => UZ [sort] => 3 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) ) [files] => Array ( ) [main_author] => stdClass Object ( [id] => 14 [abstract_id] => 15 [vorname] => Jamol [name] => Uzokov [qualification] => [institution] => Republican specialized scientific practical medical center of therapy and medical rehabilitation [ort] => Tashkent [land] => UZ [sort] => 1 [is_presenting_author] => yes [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_contact] =>
Jamol Uzokov
UZ-100084 Tashkent
jml_uz@yahoo.com ) [session] => stdClass Object ( [id] => 1 [name] => Poster [date] => 2019-05-09 [start] => 00:00:00 [end] => 00:00:00 [abbr] => P [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_authors] => J. Uzokov1, A. Alyavi1, S. Azizov1, B. Alyavi1 (1Tashkent UZ) [detail_url] => https://www.iscp2019.com/abstracts/presentation/1 )